Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734430 · ClinicalTrials.gov registry record
Genetics of Appendix Cancer Study
A clinical trial of Appendiceal Cancer and Appendix Cancer, sponsored by Andreana Holowatyj, PhD, MSCI.
- Recruiting
- Registry status
- 700
- Enrollment target
- 1
- Study location
NCT05734430: Recruiting study of Appendiceal Cancer and Appendix Cancer, sponsored by Andreana Holowatyj, PhD, MSCI.
NCT05734430 is a study of Appendiceal Cancer and Appendix Cancer that is actively recruiting participants, run by Andreana Holowatyj, PhD, MSCI. The registered enrollment target is 700 participants, above the 71-participant average among 6 other Appendiceal Cancer trials with a reported enrollment target (886% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05734430, a study of Appendiceal Cancer and Appendix Cancer, is actively recruiting participants, sponsored by Andreana Holowatyj, PhD, MSCI.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 1
- Study location
Study Summary
The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.
Conditions Studied
Interventions
- GENETIC Genetic profiling
- OTHER Retrospective tissue procurement
Study Locations (1)
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2034-11 |
What NCT05734430 shows while recruiting
NCT05734430 is an observational study that tracks outcomes without assigning an intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 71-participant average among 6 other Appendiceal Cancer trials with a reported enrollment target (886% higher).
The record links to 10 conditions, with Appendiceal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Genetic profiling is the first listed.
NCT05734430 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05734430 about?
NCT05734430 is a clinical study titled "Genetics of Appendix Cancer Study". The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.
What is the current status of trial NCT05734430?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2022-11-11. Estimated completion is 2034-11.
What conditions does trial NCT05734430 study?
This clinical trial studies the following conditions: Appendiceal Cancer, Appendix Cancer, Appendiceal Neoplasms, Appendiceal Adenocarcinoma, Appendix Adenocarcinoma.
What interventions are being tested in trial NCT05734430?
The interventions under investigation include: Genetic profiling (GENETIC), Retrospective tissue procurement (OTHER).
Who is sponsoring clinical trial NCT05734430?
This trial is sponsored by Andreana Holowatyj, PhD, MSCI, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734430 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Appendiceal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
RECRUITING · Phase 1
-
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
RECRUITING · NA
-
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
RECRUITING · NA
-
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
RECRUITING · Phase 4
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI